|
1
|
Perivoliotis K, Baloyiannis I, Samara AA, Koutoukoglou P, Ntellas P, Dadouli K, Ioannou M, Tepetes K. Microvessel density in patients with gastrointestinal stromal tumors: A systematic review and meta-analysis. World J Methodol 2023; 13:153-165. [PMID: 37456971 PMCID: PMC10348082 DOI: 10.5662/wjm.v13.i3.153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/14/2023] [Revised: 04/30/2023] [Accepted: 05/16/2023] [Indexed: 06/20/2023] Open
Abstract
BACKGROUND Gastrointestinal stromal tumors (GISTs) are considered the most common mesenchymal tumors of the gastrointestinal tract. Microvessel density (MVD) constitutes a direct method of vascularity quantification and has been associated with survival rates in multiple malignancies. AIM To appraise the effect of MVD on the survival of patients with GIST. METHODS This study adhered to Systematic reviews and Meta-Analyses guidelines and the Cochrane Handbook for Systematic Reviews of Interventions. Electronic scholar databases and grey literature repositories were systematically screened. The Fixed Effects or Random Effects models were used according to the Cochran Q test. RESULTS In total, 6 eligible studies were identified. The pooled hazard ratio (HR) for disease free survival (DFS) was 8.52 (95%CI: 1.69-42.84, P = 0.009). The odds ratios of disease-free survival between high and low MVD groups at 12 and 60 mo did not reach statistical significance. Significant superiority of the low MVD group in terms of DFS was documented at 36 and 120 mo (OR: 8.46, P < 0.0001 and OR: 22.71, P = 0.0003, respectively) as well as at metastases rate (OR: 0.11, P = 0.0003). CONCLUSION MVD significantly correlates with the HR of DFS and overall survival rates at 36 and 120 mo. Further prospective studies of higher methodological quality are required.
Collapse
Affiliation(s)
| | - Ioannis Baloyiannis
- Department of Surgery, University Hospital of Larissa, Larissa 41110, Greece
| | - Athina A Samara
- Department of Surgery, University Hospital of Larissa, Larissa 41110, Greece
| | - Prodromos Koutoukoglou
- Research Methodology in Biomedicine, Biostatistics and Clinical Bioinformatics, University of Thessaly, 41110 41110, Greece
| | - Panagiotis Ntellas
- Department of Pathology, University Hospital of Larissa, Larissa 41110, Greece
| | - Katerina Dadouli
- Research Methodology in Biomedicine, Biostatistics and Clinical Bioinformatics, University of Thessaly, 41110 41110, Greece
| | - Maria Ioannou
- Department of Pathology, University Hospital of Larissa, Larissa 41110, Greece
| | | |
Collapse
|
|
2
|
Li GC, Xin L, Wang YS, Chen Y. Long Intervening Noncoding 00467 RNA Contributes to Tumorigenesis by Acting as a Competing Endogenous RNA against miR-107 in Cervical Cancer Cells. THE AMERICAN JOURNAL OF PATHOLOGY 2019; 189:2293-2310. [PMID: 31640853 DOI: 10.1016/j.ajpath.2019.07.012] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/19/2018] [Revised: 06/21/2019] [Accepted: 07/09/2019] [Indexed: 12/14/2022]
Abstract
The functional roles of individual large intervening noncoding RNAs in carcinogenesis and progression of cervical cancer have been uncovered in previous studies. In this study, we aimed to identify the role of long intervening noncoding 00467 (LINC00467) in epithelial-mesenchymal transition (EMT), invasion and migration of cervical cancer cells by regulating miR-107 and kinesin family member 23 (KIF23). Microarray analyses were used to detect cervical cancer-related differentially expressed genes, followed by determination of LINC00467, miR-107, and KIF23 levels and subcellular location of LINC00467. Cervical cancer cells were treated with a series of siRNA and mimics to measure the regulatory role of LINC00467, miR-107, and KIF23 in EMT, cell invasion, migration and proliferation, and tumorigenic ability in vivo and in vitro. LINC00467 and KIF23 were highly expressed, whereas miR-107 was poorly expressed, in cervical cancer. LINC00467 was found to be primarily located in the cytoplasm and function as a competing endogenous RNA against miR-107 to suppress KIF23. Cell proliferation, migration, invasion, and EMT in vitro were inhibited as a result of lentiviral-mediated LINC00467 knockdown and miR-107 overexpression in cervical cancer. In addition, LINC00467 silencing or miR-107 up-regulation repressed tumorigenic ability in xenograft tumor-bearing nude mice in cervical cancer in vivo. LINC00467 silencing or miR-107 up-regulation may serve as novel potential strategies for the treatment of cervical cancer.
Collapse
Affiliation(s)
- Guang-Cai Li
- Department of Obstetrics and Gynecology, Linyi People's Hospital, Linyi, People's Republic of China
| | - Li Xin
- Sense Control Office, Economic and Technological Development Zone, People's Hospital of Linyi, Linyi, People's Republic of China
| | - Yong-Sheng Wang
- Department of Obstetrics and Gynecology, Linyi People's Hospital, Linyi, People's Republic of China
| | - Ying Chen
- Department of Obstetrics and Gynecology, Linyi People's Hospital, Linyi, People's Republic of China.
| |
Collapse
|
|
3
|
Zajkowska M, Zbucka-Krętowska M, Sidorkiewicz I, Lubowicka E, Będkowska GE, Gacuta E, Szmitkowski M, Ławicki S. Human Plasma Levels of Vascular Endothelial Growth Factor, Matrix Metalloproteinase 9, and Tissue Inhibitor of Matrix Metalloproteinase 1 and Their Applicability as Tumor Markers in Diagnoses of Cervical Cancer Based on ROC Analysis. Cancer Control 2018; 25:1073274818789357. [PMID: 30037277 PMCID: PMC6058422 DOI: 10.1177/1073274818789357] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Cervical cancer (CC) remains a major diagnostic problem. The introduction of
human papillomavirus vaccination significantly reduced the number of new cases;
however, the search for new methods that would earlier indicate the development
of cancerous changes is vital. The aim of this study was to investigate the
diagnostic power of those parameters in comparison to Cancer Antigen 125 (CA
125) and Squamous Cell Carcinoma Antigen (SCC-Ag) in patients with CC and in
relation to the control group. The study included 100 patients with CC and 50
healthy women. Plasma levels of tested parameters were determined by
enzyme-linked immunosorbent assay, CA 125, and SCC-Ag by chemiluminescent
microparticle immunoassay. Plasma levels of all parameters in the total cancer
group showed statistical significance (in all cases P <
.05). In stage I cancer, only vascular endothelial growth factor (VEGF) and
tissue inhibitors of metalloproteinase 1; in stage II, all the tested parameters
and CA 125; and in stage III + IV, VEGF, matrix metalloproteinase 9 (MMP-9), and
CA 125 showed statistical significance when compared to the healthy volunteers
group. Vascular endothelial growth factor showed the highest value of
sensitivity from all tested parameters (I: 75%, II: 76%, III + IV: 94%, and 82%
in total CC group). The highest specificity was obtained by MMP-9 (94%). In the
total CC, stage I, and stage II groups, all tested parameters showed
statistically significant area under the receiver operating characteristics
curve (AUC), but maximum range was obtained for the combination VEGF + SCC-Ag
(I: 0.9146, II: 0.8941, III + IV: 0.9139, total CC group: 0.9347). The combined
analysis of tested parameters and tumor markers resulted in an increase in
sensitivity and AUC values, which provides hope for developing new panel of
biomarkers that may be used in the diagnosis of CC in the future.
Collapse
Affiliation(s)
- Monika Zajkowska
- 1 Department of Biochemical Diagnostics, Medical University of Bialystok, Bialystok, Poland
| | - Monika Zbucka-Krętowska
- 2 Department of Reproduction and Gynecological Endocrinology, Medical University of Bialystok, Bialystok, Poland
| | - Iwona Sidorkiewicz
- 2 Department of Reproduction and Gynecological Endocrinology, Medical University of Bialystok, Bialystok, Poland
| | - Emilia Lubowicka
- 3 Department of Esthetic Medicine, Medical University of Bialystok, Bialystok, Poland
| | - Grażyna Ewa Będkowska
- 4 Department of Haematological Diagnostics, Medical University of Bialystok, Bialystok, Poland
| | - Ewa Gacuta
- 5 Department of Perinatology, Medical University of Bialystok, Bialystok, Poland
| | - Maciej Szmitkowski
- 1 Department of Biochemical Diagnostics, Medical University of Bialystok, Bialystok, Poland
| | - Sławomir Ławicki
- 1 Department of Biochemical Diagnostics, Medical University of Bialystok, Bialystok, Poland
| |
Collapse
|
|
4
|
Junker P, Puppe J, Thangarajah F, Domröse C, Cepic A, Morgenstern B, Ratiu D, Hellmich M, Mallmann P, Wirtz M. Neoadjuvant Therapy of Cervical Carcinoma with the Angiogenesis Inhibitor Bevacizumab: a Single-Centre Analysis. Geburtshilfe Frauenheilkd 2018; 78:768-774. [PMID: 30158716 PMCID: PMC6109715 DOI: 10.1055/a-0641-5588] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2018] [Revised: 06/07/2018] [Accepted: 06/08/2018] [Indexed: 01/28/2023] Open
Abstract
Introduction
Cervical cancer is the fourth most frequent cancer in women worldwide. Addition of the VEGF antibody bevacizumab in combination with platinum-containing chemotherapy achieved an improvement in overall survival in advanced cervical cancer. To date there are no data on neoadjuvant use of bevacizumab. We therefore studied the benefit of neoadjuvant combined therapy with bevacizumab in a group of cervical cancer patients.
Patients and Methods
This retrospective cohort study analysed 14 patients with cervical cancer FIGO stages 1b1 to IV who received neoadjuvant platinum-containing chemotherapy in combination with bevacizumab. The comparative cohort consisted of 16 patients who were treated with neoadjuvant platinum-containing chemotherapy alone. The response rates were determined by means of preoperative clinical examination, diagnostic imaging (RECIST), changes in tumour markers (SCC) and by histopathology.
Results
A clinical response was found in 93.8% (n = 15) of patients after bevacizumab-free therapy and in 100% (n = 14) of the patients who were treated with bevacizumab in addition. Combined therapy with bevacizumab led to a higher rate of clinical complete remission (42.9 vs. 12.5%; p = 0.072) and significantly improved the reduction in tumour size (Δ longest diameter: 3.7 vs. 2.5 cm; p = 0.025). Downgrading was observed in 100% of all patients treated with bevacizumab compared with 75% in the control arm. The rate of pathological complete remission (pCR) was not altered significantly (28.6% [n = 4] vs. 37.5% [n = 6]; p = 0.460).
Discussion
Overall, combined therapy with bevacizumab led to a better clinical response. Operability was therefore improved more often. Because of the small patient cohort, larger prospective studies are necessary to validate the effect of neoadjuvant combined therapy with bevacizumab.
Collapse
Affiliation(s)
- Philip Junker
- Uniklinik Köln, Klinik und Poliklinik für Gynäkologie und Geburtshilfe, Köln, Germany
| | - Julian Puppe
- Uniklinik Köln, Klinik und Poliklinik für Gynäkologie und Geburtshilfe, Köln, Germany
| | - Fabinshy Thangarajah
- Uniklinik Köln, Klinik und Poliklinik für Gynäkologie und Geburtshilfe, Köln, Germany
| | - Christian Domröse
- Uniklinik Köln, Klinik und Poliklinik für Gynäkologie und Geburtshilfe, Köln, Germany
| | - Angela Cepic
- Uniklinik Köln, Klinik und Poliklinik für Gynäkologie und Geburtshilfe, Köln, Germany
| | - Bernd Morgenstern
- Uniklinik Köln, Klinik und Poliklinik für Gynäkologie und Geburtshilfe, Köln, Germany
| | - Dominik Ratiu
- Uniklinik Köln, Klinik und Poliklinik für Gynäkologie und Geburtshilfe, Köln, Germany
| | - Martin Hellmich
- Uniklinik Köln, Institut für Medizinische Statistik, Informatik und Epidemiologie, Köln, Germany
| | - Peter Mallmann
- Uniklinik Köln, Klinik und Poliklinik für Gynäkologie und Geburtshilfe, Köln, Germany
| | - Marina Wirtz
- Uniklinik Köln, Klinik und Poliklinik für Gynäkologie und Geburtshilfe, Köln, Germany
| |
Collapse
|
|
5
|
Barillari G, Monini P, Sgadari C, Ensoli B. The Impact of Human Papilloma Viruses, Matrix Metallo-Proteinases and HIV Protease Inhibitors on the Onset and Progression of Uterine Cervix Epithelial Tumors: A Review of Preclinical and Clinical Studies. Int J Mol Sci 2018; 19:E1418. [PMID: 29747434 PMCID: PMC5983696 DOI: 10.3390/ijms19051418] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2018] [Revised: 05/03/2018] [Accepted: 05/04/2018] [Indexed: 12/15/2022] Open
Abstract
Infection of uterine cervix epithelial cells by the Human Papilloma Viruses (HPV) is associated with the development of dysplastic/hyperplastic lesions, termed cervical intraepithelial neoplasia (CIN). CIN lesions may regress, persist or progress to invasive cervical carcinoma (CC), a leading cause of death worldwide. CIN is particularly frequent and aggressive in women infected by both HPV and the Human Immunodeficiency Virus (HIV), as compared to the general female population. In these individuals, however, therapeutic regimens employing HIV protease inhibitors (HIV-PI) have reduced CIN incidence and/or clinical progression, shedding light on the mechanism(s) of its development. This article reviews published work concerning: (i) the role of HPV proteins (including HPV-E5, E6 and E7) and of matrix-metalloproteinases (MMPs) in CIN evolution into invasive CC; and (ii) the effect of HIV-PI on events leading to CIN progression such as basement membrane and extracellular matrix invasion by HPV-positive CIN cells and the formation of new blood vessels. Results from the reviewed literature indicate that CIN clinical progression can be monitored by evaluating the expression of MMPs and HPV proteins and they suggest the use of HIV-PI or their derivatives for the block of CIN evolution into CC in both HIV-infected and uninfected women.
Collapse
Affiliation(s)
- Giovanni Barillari
- Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, 1 via Montpellier, 00133 Rome, Italy.
| | - Paolo Monini
- National HIV/AIDS Research Center, Istituto Superiore di Sanità, 299 viale Regina Elena, 00161 Rome, Italy.
| | - Cecilia Sgadari
- National HIV/AIDS Research Center, Istituto Superiore di Sanità, 299 viale Regina Elena, 00161 Rome, Italy.
| | - Barbara Ensoli
- National HIV/AIDS Research Center, Istituto Superiore di Sanità, 299 viale Regina Elena, 00161 Rome, Italy.
| |
Collapse
|
|
6
|
Nyström H, Jönsson M, Werner-Hartman L, Nilbert M, Carneiro A. Hypoxia-inducible factor 1α predicts recurrence in high-grade soft tissue sarcoma of extremities and trunk wall. J Clin Pathol 2017; 70:879-885. [DOI: 10.1136/jclinpath-2016-204149] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2016] [Revised: 12/21/2016] [Accepted: 03/19/2017] [Indexed: 12/25/2022]
|
|
7
|
Becker AS, Perucho JA, Wurnig MC, Boss A, Ghafoor S, Khong PL, Lee EYP. Assessment of Cervical Cancer with a Parameter-Free Intravoxel Incoherent Motion Imaging Algorithm. Korean J Radiol 2017; 18:510-518. [PMID: 28458603 PMCID: PMC5390620 DOI: 10.3348/kjr.2017.18.3.510] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2016] [Accepted: 11/13/2016] [Indexed: 12/20/2022] Open
Abstract
Objective To evaluate the feasibility of a parameter-free intravoxel incoherent motion (IVIM) approach in cervical cancer, to assess the optimal b-value threshold, and to preliminarily examine differences in the derived perfusion and diffusion parameters for different histological cancer types. Materials and Methods After Institutional Review Board approval, 19 female patients (mean age, 54 years; age range, 37–78 years) gave consent and were enrolled in this prospective magnetic resonance imaging study. Clinical staging and biopsy results were obtained. Echo-planar diffusion weighted sequences at 13 b-values were acquired at 3 tesla field strength. Single-sliced region-of-interest IVIM analysis with adaptive b-value thresholds was applied to each tumor, yielding the optimal fit and the optimal parameters for pseudodiffusion (D*), perfusion fraction (Fp) and diffusion coefficient (D). Monoexponential apparent diffusion coefficient (ADC) was calculated for comparison with D. Results Biopsy revealed squamous cell carcinoma in 10 patients and adenocarcinoma in 9. The b-value threshold (median [interquartile range]) depended on the histological type and was 35 (22.5–50) s/mm2 in squamous cell carcinoma and 150 (100–150) s/mm2 in adenocarcinoma (p < 0.05). Comparing squamous cell vs. adenocarcinoma, D* (45.1 [25.1–60.4] × 10−3 mm2/s vs. 12.4 [10.5–21.2] × 10−3 mm2/s) and Fp (7.5% [7.0–9.0%] vs. 9.9% [9.0–11.4%]) differed significantly between the subtypes (p < 0.02), whereas D did not (0.89 [0.75–0.94] × 10−3 mm2/s vs. 0.90 [0.82–0.97] × 10−3 mm2/s, p = 0.27). The residuals did not differ (0.74 [0.60–0.92] vs. 0.94 [0.67–1.01], p = 0.32). The ADC systematically underestimated the magnitude of diffusion restriction compared to D (p < 0.001). Conclusion The parameter-free IVIM approach is feasible in cervical cancer. The b-value threshold and perfusion-related parameters depend on the tumor histology type.
Collapse
Affiliation(s)
- Anton S Becker
- Institute of Diagnostic and Interventional Radiology, University Hospital of Zurich, Zurich 8091, Switzerland
| | - Jose A Perucho
- Department of Diagnostic Radiology, The University of Hong Kong, Hong Kong, China
| | - Moritz C Wurnig
- Institute of Diagnostic and Interventional Radiology, University Hospital of Zurich, Zurich 8091, Switzerland
| | - Andreas Boss
- Institute of Diagnostic and Interventional Radiology, University Hospital of Zurich, Zurich 8091, Switzerland
| | - Soleen Ghafoor
- Institute of Diagnostic and Interventional Radiology, University Hospital of Zurich, Zurich 8091, Switzerland
| | - Pek-Lan Khong
- Department of Diagnostic Radiology, The University of Hong Kong, Hong Kong, China
| | - Elaine Y P Lee
- Department of Diagnostic Radiology, The University of Hong Kong, Hong Kong, China
| |
Collapse
|
|
8
|
Lin C, Zhang Z, Xu Y, Wang R, Chen S, Gao J, Wang D, Huang Q, Tu X, Wang L. High Tumor Vascular Endothelial Growth Factor Expression Is Associated With Poorer Clinical Outcomes in Resected T3 Gastric Adenocarcinoma. Am J Clin Pathol 2016; 146:278-88. [PMID: 27543975 DOI: 10.1093/ajcp/aqw110] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
OBJECTIVES To investigate the clinical and prognostic significance of high vascular endothelial growth factor (VEGF) expression in resected T3 gastric adenocarcinoma (GA). METHODS Data of VEGF expression on 453 patients with resected T3 GA were collected from a single institute in Fuzhou, China. VEGF expression in the resected tumor tissues was evaluated by immunohistochemistry (IHC). Associations between VEGF expression outcomes and prognosis were investigated using by the χ(2) test, Kaplan-Meier plus log-rank test, and univariate and multivariate Cox models. RESULTS In total, 48.6% (220/453) patients had low VEGF expression (IHC score ≤2+). Patients with high VEGF expression (IHC>2+; 233/453, 51.4%) had significantly poorer median recurrence-free survival time (20 vs 55 months, P < 001) and median overall survival time (28 vs 58 months; P < 001) than patients with low VEGF. High VEGF was associated with higher overall recurrence (68.2% vs 51.4%, P = 2.675 × 10(-4)), poorer overall survival (27.5% vs 47.3%, P = 1.719 × 10(-5)), and increased risk of recurrence (hazard ratio [HR], 1.71; 95% confidence interval [CI], 1.33-2.19; P = 2.43 × 10(-5)) and death (HR, 1.80; 95% CI, 1.41-2.3; P = 2.19 × 10(-6)). CONCLUSIONS High VEGF expression is associated with a higher risk of recurrence and shorter survival in resected T3 GA. These findings may provide a foundation for evaluating VEGF-targeted molecular therapies in T3 GA.
Collapse
Affiliation(s)
- Chen Lin
- From the Department of General Surgery
| | | | - Yun Xu
- Department of Oncology, 174th Hospital of Chinese PLA, Xiamen, China
| | - Ruohan Wang
- Department of Biomedical Engineering, College of Engineering, Boston University, Boston, MA
| | | | - Jian Gao
- Fujian University of Traditional Chinese Medicine, Fuzhou, China
| | - Daiyong Wang
- Clinical Institute of Fuzhou General Hospital, Fujian Medical University, Fuzhou, China
| | - Qiaojia Huang
- Department of Experimental Medicine, Fuzhou General Hospital (Dongfang Hospital), Fuzhou, China
| | - Xiaohuang Tu
- From the Department of General Surgery Clinical Institute of Fuzhou General Hospital, Fujian Medical University, Fuzhou, China.
| | - Lie Wang
- From the Department of General Surgery Clinical Institute of Fuzhou General Hospital, Fujian Medical University, Fuzhou, China.
| |
Collapse
|
|
9
|
Meng F, Tan S, Liu T, Song H, Lou G. Predictive significance of combined LAPTM4B and VEGF expression in patients with cervical cancer. Tumour Biol 2015; 37:4849-55. [PMID: 26526574 DOI: 10.1007/s13277-015-4319-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2015] [Accepted: 10/26/2015] [Indexed: 12/28/2022] Open
Abstract
Lysosome-associated protein transmembrane 4ß-35 (LAPTM4B-35) is overexpressed in several solid malignancies. This study determines the expression level of LAPTM4B-35 in the cervical cancer during tumor development and progression. The present study investigated the clinicopathological significance of the coexpression of LAPTM4B-35 and VEGF in patients with cervical cancer. Immunohistochemistry was used to evaluate the expression of LAPTM4B-35 and VEGF in 62 cervical intraepithelial neoplasia (CIN) and 226 cervical carcinoma in comparison with 45 normal cervical specimens. The correlation of combined LAPTM4B-35 and VEGF with clinicopathologic characteristics was analyzed using a chi-squared test. Patient survival was determined using Kaplan-Meier method and log-rank test. A Cox regression analysis was performed to determine the prognostic significance of the factors. Combined LAPTM4B-35 and VEGF expression was significantly associated with FIGO stage (P = 0.014), tumor histologic grade (P = 0.033), lymph node metastasis (P = 0.045), and recurrence (P = 0.010). Kaplan-Meier survival analysis showed that patients with cervical cancer expressing both LAPTM4B-35 and VEGF exhibited both poor overall survival (OS) and disease-free survival (DFS) (P = 0.015 and P = 0.016, respectively). Cox analysis demonstrated that combined LAPTM4B-35 and VEGF expression was an independent factor for both OS and DFS (P = 0.015 and P = 0.016, respectively). Overexpression of LAPTM4B-35combined with positive VEGF expression may serve as a new biological marker to predict the prognosis of cervical carcinoma patients.
Collapse
Affiliation(s)
- Fanling Meng
- Department of Gynecology, The Affiliated Tumor Hospital, Harbin Medical University, Harbin, China
| | - Shu Tan
- Department of Gynecology, The Affiliated Tumor Hospital, Harbin Medical University, Harbin, China
| | - Tianbo Liu
- Department of Gynecology, The Affiliated Tumor Hospital, Harbin Medical University, Harbin, China
| | - Hongtao Song
- Department of Pathology, The Affiliated Tumor Hospital, Harbin Medical University, Harbin, China
| | - Ge Lou
- Department of Gynecology, The Affiliated Tumor Hospital, Harbin Medical University, Harbin, China.
| |
Collapse
|